Slonin Jonathan sold 3,040 shares of Pacira BioSciences, Inc. at $23.23 for −$70.6k on Aug 17, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Chief Medical Officer
Chief Medical Officer
Filed Aug 18, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$70,619.20Shares × reported price
Shares traded
3,040Common Stock
Price per share
$23.23Reported price. Read footnotes for ranges.
% of reported position traded
1.39%This security and ownership context
Holdings after
216,383.646Direct
Trade date
Aug 17, 2026Sell
Filed
Aug 18, 2026, 5:21 PM ET1-day reporting delay
Accession
0001628280-26-057759Code S · Transaction 3177
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 219,423.646 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

PCRX price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
PCRX · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +6.7%1w ago +1.8%1d ago −4.2%
Returns since7d +3.8%30d +2%90d180d1y

Footnotes in full

F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on August 12, 2025. F2: Includes 511.471 shares of common stock acquired under the issuer's employee stock purchase plan in June 2026.